1. Apoptosis
  2. Apoptosis
  3. Erucin

Erucin (ERU) is an isothiocyanate particularly abundant in arugula. Erucin shows anticancer, neuroprotective, and anti-inflammatory activities.

For research use only. We do not sell to patients.

Erucin Chemical Structure

Erucin Chemical Structure

CAS No. : 4430-36-8

Size Price Stock Quantity
5 mg USD 32 In-stock
10 mg USD 50 In-stock
25 mg USD 110 In-stock
50 mg USD 180 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Erucin (ERU) is an isothiocyanate particularly abundant in arugula. Erucin shows anticancer, neuroprotective, and anti-inflammatory activities[1][2][3][4].

In Vitro

Erucin (ERU) (0-100 μM) releases H2S and inhibits cell viability in AsPC‐1 cells in a concentration-dependent manner[1].
Erucin inhibits cell migration and altered the AsPC‐1 cell cycle, reducing G0/G1 phase and increasing G2/M and S phases[1].
Erucin (30 μM, 72 h) induces AsPC‐1 cell apoptosis and inhibits cell migration[1].
Erucin reduces levels of phosphorylated ERK1/2 in AsPC‐1 cells[1].
Erucin (0-200 μM, 24 h) shows antiproliferative activity with an IC50 of 97.7 µM in A549 cells[2].
Erucin (0-50 μM, 24 h) induces the cleavage of PARP-1 at 50 µM, and increases p53 and p21 protein expression in A549 cells[2].
Erucin decreases LPS-induced production of NO, prostaglandin E2 (PGE2), TNF-α, IL-6 and IL-1β in RAW 264.7 cells[3].
Erucin decreases LPS-induced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 in RAW 264.7 cells[3].
Erucin inhibits LPS-induced activation of NFκB Signaling in RAW 264.7 cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: AsPC‐1
Concentration: 10, 30, and 100 μM
Incubation Time: 72 h
Result: Showed a significant and concentration‐dependent reduction of cell viability.

Cell Cycle Analysis[1]

Cell Line: AsPC‐1
Concentration: 30 μM
Incubation Time: 72 h
Result: Showed a particular increase of cells number in the G2/M phase (36.6% ± 3.5 vs. vehicle‐treated cells in the G2/M phase: 24.0% ± 1.3) and in the S‐phase (18.1% ± 1.5 vs. vehicle‐treated cells in the S phase: 11.0% ± 0.7) and a consequent significant reduction of cells in the G0/G1 phase (35.1% ± 5.0 vs. vehicle‐treated cells in the G0/G1 phase: 59.5% ± 1.8.

Apoptosis Analysis[1]

Cell Line: AsPC‐1
Concentration: 30 μM
Incubation Time: 72 h
Result: Significantly increased the number of total apoptotic cells (apoptotic dead cells and apoptotic live cells; vehicle: 17.7% ± 2.5 vs. Erucin: 28.7% ± 4.2).

Cell Proliferation Assay[2]

Cell Line: A549
Concentration: 0-200 µM
Incubation Time: 24 h
Result: Showed antiproliferative effect with an IC50 of 97.7 µM.

Western Blot Analysis[2]

Cell Line: A549
Concentration: 0-50 µM
Incubation Time: 24 h
Result: Induced the cleavage of PARP-1 at 50 µM. Increased p53 and p21 protein expression.

Western Blot Analysis[3]

Cell Line: RAW 264.7
Concentration: 0, 2.5, and 5 µM
Incubation Time: 30 min
Result: Decreased the expression of iNOS and COX-2 induced by LPS. Suppressed the LPS-induced reduction in IκB-α. Suppressed NFκB DNA binding and transcriptional activity.

RT-PCR[3]

Cell Line: RAW 264.7
Concentration: 0, 2.5, and 5 µM
Incubation Time: 24 h
Result: Decreased LPS-induced TNF-α, IL-6 and IL-1β production.
In Vivo

Erucin (ERU) (0-300 nM) significantly inhibits TPA-induced edema formation[3].
Erucin (30 μmol/kg; i.p.; twice a week for 4 week) shows neuroprotective effects[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female ICR mice (4 weeks of age), TPA (12-O-tetradecanoylphorbol-13-acetate)-induced mouse ear edema model[3]
Dosage: 0, 100, and 300 nM
Administration: Topically applied to the mouse ear 30 min prior to the topical application of TPA
Result: Significantly inhibited TPA-induced edema formation.
Animal Model: Male C57Bl/6 mice (9 weeks old, 25–30 g body weight)[4]
Dosage: 30 μmol/kg
Administration: Intraperitoneal administration, twice a week, 4 weeks (Induce brain lesion by intrastriatal injection of 6-OHDA)
Result: Induced a partial recovery in the rotational behavior test. Upregulated the expression of TH. Counteract neuronal death and DNA fragmentation in 6-OHDA lesioned mice. increase total GSH and Nrf2 levels in 6-OHDA lesioned mice.
Molecular Weight

161.29

Formula

C6H11NS2

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

CSCCCCN=C=S

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (620.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.2000 mL 31.0001 mL 62.0001 mL
5 mM 1.2400 mL 6.2000 mL 12.4000 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (15.50 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (15.50 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 6.2000 mL 31.0001 mL 62.0001 mL 155.0003 mL
5 mM 1.2400 mL 6.2000 mL 12.4000 mL 31.0001 mL
10 mM 0.6200 mL 3.1000 mL 6.2000 mL 15.5000 mL
15 mM 0.4133 mL 2.0667 mL 4.1333 mL 10.3334 mL
20 mM 0.3100 mL 1.5500 mL 3.1000 mL 7.7500 mL
25 mM 0.2480 mL 1.2400 mL 2.4800 mL 6.2000 mL
30 mM 0.2067 mL 1.0333 mL 2.0667 mL 5.1667 mL
40 mM 0.1550 mL 0.7750 mL 1.5500 mL 3.8750 mL
50 mM 0.1240 mL 0.6200 mL 1.2400 mL 3.1000 mL
60 mM 0.1033 mL 0.5167 mL 1.0333 mL 2.5833 mL
80 mM 0.0775 mL 0.3875 mL 0.7750 mL 1.9375 mL
100 mM 0.0620 mL 0.3100 mL 0.6200 mL 1.5500 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Erucin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Erucin
Cat. No.:
HY-121323
Quantity:
MCE Japan Authorized Agent: